Mechanism of Action
CRFR2 Selectivity
UCN3 is approximately 100-fold selective for CRFR2 over CRFR1. In the hypothalamus and limbic system, CRFR2 activation by UCN3 modulates stress responses and anxiety-related behaviors in a manner generally opposite to CRFR1 activation by CRF. UCN3 has anxiolytic-like properties in rodent models, consistent with a role in stress recovery rather than initiation.
Pancreatic Effects
UCN3 is expressed in pancreatic beta-cells and acts in an autocrine/paracrine manner to amplify glucose-stimulated insulin secretion. CRFR2 activation in beta-cells increases cAMP and augments the incretin effect. UCN3 expression is upregulated following glucose challenge and may coordinate beta-cell function with nutritional state.
Research Summary
Stress and Anxiety
PreclinicalUCN3 administration into the central nucleus of the amygdala produces anxiolytic effects in rat models. This contrasts with CRF, which produces anxiogenic effects via CRFR1. UCN3-knockout mice show altered stress responsivity, suggesting endogenous UCN3 buffers the acute stress response and accelerates recovery.
Type 2 Diabetes
PreclinicalUCN3 is reduced in pancreatic islets in diabetic rodent models and in human type 2 diabetes. Restoring UCN3 signaling through CRFR2 agonists enhances glucose-stimulated insulin secretion. UCN3 may be a useful biomarker of beta-cell function and a therapeutic target for beta-cell preservation in early diabetes.
Calculate your Urocortin-3 dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Anxiety models (rodent) | 100-300 ng ICV | Single | Intracerebroventricular |
| Insulin secretion studies | 10-100 nM | Acute | Islet incubation |
Preclinical research only. No human clinical data available.
Interactions
Safety Profile
UCN3 is an endogenous mammalian peptide; physiological roles suggest baseline safety. Exogenous UCN3 may cause hypotension and flushing through vascular CRFR2 activation. No human clinical data available. The selective CRFR2 profile reduces HPA axis activation concerns relative to CRF or UCN1.
References
- [1]Lewis K et al. (2001). Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. PNAS, 98(13), 7570-7575.
- [2]van der Meulen T et al. (2015). Urocortin3 mediates somatostatin-dependent negative feedback control of insulin secretion. Nature Medicine, 21(7), 769-776.